Biotech company Nuclera has appointed William J. Kullback to its Board of Directors.
Bill will join the company as a Non-Executive Director, bringing more than 30 years of experience in life science tool manufacturing leadership to the team.
Alongside the other board members, Bill will be responsible for devising and implementing the company's global commercial expansion strategy.
This follows the successful closing of Nuclera's USD $75m series C round.
Mr Kullback has been the Chief Financial Officer of Telesis Bio — a drug discovery tech company — since August 2023, in which time he has restructured the business' operational expenses; resulting in a 70% decrease.
He recently worked for BioLegend as the CFO, where he helped manage the company's $5.25bn sale to Revvity.
Bill also negotiated and closed acquisitions and investments whilst CFO at NASDAQ listed medical device company, Lombard Medical, prior to its acquisition by Shanghai-based MicroPort Scientific Corporation.
Dr Michael Chen, CEO and co-founder, Nuclera, commented: “I am pleased to welcome Bill to the Nuclera board. His distinguished career and financial expertise will be instrumental as we push forward with our growth strategy in line with our commercial goals.” He added: “Bill’s experience will be invaluable to Nuclera as we scale to address current challenges in protein production by bringing eProtein Discovery to even more researchers.”
Bill Kullback, Non-Executive Board Director, Nuclera, added: “Nuclera’s eProtein Discovery has the potential to transform drug discovery workflows. The Company is at an exciting stage as it expands globally and I am looking forward to working with the team to support the Company’s growth and drive success at this pivotal stage in Nuclera’s development.”
